<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00909636</url>
  </required_header>
  <id_info>
    <org_study_id>M11-031</org_study_id>
    <nct_id>NCT00909636</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of the ABT-333 Tablet</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333 in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability and pharmacokinetics of&#xD;
      escalating multiple doses of the ABT-333 tablet formulation in healthy adult subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess multiple dose safety and tolerability of an ABT-333 tablet formulation relative to placebo by the evaluation of vital signs, ECGs, physical exams, clinical lab testing and adverse event monitoring.</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Values for the pharmacokinetic parameters of ABT-333 will be evaluated after pre- and post-dose blood draws.</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>HCV Infection</condition>
  <arm_group>
    <arm_group_label>1. ABT-333 Tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three 400mg ABT-333 Tablets, BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. ABT-333 Tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Four 400mg ABT-333 Tablets, BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3. Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Three or four placebo tablets, BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-333</intervention_name>
    <description>See arm description for more information</description>
    <arm_group_label>1. ABT-333 Tablet</arm_group_label>
    <arm_group_label>2. ABT-333 Tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>See arm description for more information</description>
    <arm_group_label>3. Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  overall healthy subjects between the ages of 18 to 55 years old;&#xD;
&#xD;
          -  if female, subject must be either postmenopausal for at least 2 years or surgically&#xD;
             sterile;&#xD;
&#xD;
          -  females must have negative results for pregnancy tests performed;&#xD;
&#xD;
          -  if male, subject must be surgically sterile or practicing at least 1 of the following&#xD;
             methods of birth control:&#xD;
&#xD;
               -  partner(s) using IUD,&#xD;
&#xD;
               -  partner(s) using oral, injected or implanted methods of hormonal contraceptives,&#xD;
&#xD;
               -  subject and/or partner(s) using double-barrier method;&#xD;
&#xD;
          -  Body Mass Index is 18 to 29, inclusive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of significant sensitivity to any drug;&#xD;
&#xD;
          -  positive test for HAV IgM, HBsAg, HCV Ab or HIV Ab;&#xD;
&#xD;
          -  history of gastrointestinal issues or procedures;&#xD;
&#xD;
          -  history of seizures, diabetes or cancer (except basal cell carcinoma);&#xD;
&#xD;
          -  clinically significant cardiovascular, respiratory (except mild asthma), renal,&#xD;
             gastrointestinal, hematologic, neurologic, thyroid, or any uncontrolled medical&#xD;
             illness or psychiatric disorder;&#xD;
&#xD;
          -  use of tobacco or nicotine-containing products with the 6-month period prior to study&#xD;
             drug administration;&#xD;
&#xD;
          -  donation or loss of 550 mL or more blood volume or receipt of a transfusion of any&#xD;
             blood product within 8 weeks prior to study drug administration;&#xD;
&#xD;
          -  clinically significant abnormal screening laboratory analyses and ECGs:&#xD;
&#xD;
               -  ALT &gt; ULN,&#xD;
&#xD;
               -  AST &gt; ULN,&#xD;
&#xD;
               -  ECG with QTcF&gt;450 msec in females and &gt;430 msec in males,&#xD;
&#xD;
               -  or ECG with 2nd or 3rd degree atrioventricular block;&#xD;
&#xD;
          -  current enrollment in another clinical study;&#xD;
&#xD;
          -  previous enrollment in this study;&#xD;
&#xD;
          -  recent (6-month) history of drug/alcohol abuse that could preclude adherence to the&#xD;
             protocol;&#xD;
&#xD;
          -  pregnant or breastfeeding female;&#xD;
&#xD;
          -  requirement for any OTC and/or prescription medication, vitamins and/or herbal&#xD;
             supplements on a regular basis or use within the 2-week period prior to the first dose&#xD;
             of study drug administration or within 10 half-lives of the respective medication;&#xD;
&#xD;
          -  use of known inhibitors or inducers of cytochrome P450 3A or cytochrome P450 2C8&#xD;
             within 1 month prior to study drug administration;&#xD;
&#xD;
          -  positive screen for drugs of abuse, alcohol, or cotinine;&#xD;
&#xD;
          -  receipt of any drug by injection within 30 days prior to study drug administration;&#xD;
&#xD;
          -  receipt of any investigational product within a time period equal to 10 half-lives of&#xD;
             the product or a minimum of 6 weeks prior to study drug administration;&#xD;
&#xD;
          -  consumption of alcohol within 48 hours prior to study drug administration;&#xD;
&#xD;
          -  consumption of grapefruit, grapefruit products, star fruit, or star fruit products&#xD;
             within the 72-hour period prior to study drug administration;&#xD;
&#xD;
          -  consideration by the investigator, for any reason, that the subject is an unsuitable&#xD;
             candidate to receive ABT-333;&#xD;
&#xD;
          -  history of cardiac disease, including family history of long-QT syndrome or&#xD;
             unexplained sudden death.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Cohen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 20081</name>
      <address>
        <city>Waukegan</city>
        <state>Illinois</state>
        <zip>60085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>May 27, 2009</study_first_submitted>
  <study_first_submitted_qc>May 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2009</study_first_posted>
  <last_update_submitted>October 11, 2010</last_update_submitted>
  <last_update_submitted_qc>October 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Daniel Cohen, MD/Study Medical Director</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <keyword>multiple ascending doses (MAD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

